Cross Shore Discovery Fund | |||||||||||||
Schedule of Investments (Unaudited) | |||||||||||||
June 30, 2023 | |||||||||||||
Portfolio Funds* | % of Net Assets | Cost(1) | Fair Value | Initial Acquisition Date | Redemption Frequency(2) |
Next Available Redemption Date |
|||||||
Long/Short Generalist: | |||||||||||||
Atika Offshore Fund, Ltd., Class A, Series 1 | 4.6% | $ 677,447 | $ 1,480,296 | 1/2/2015 | Quarterly | 9/30/2023 | |||||||
EVR Offshore Partners Fund, Ltd., Class B, Series 1121 | 5.5% | 1,750,000 | 1,774,346 | 11/1/2021 | Quarterly | 9/30/2023 | (3) | ||||||
Hawk Ridge Partners Offshore, Ltd., Class A, Initial Series | 8.7% | 1,600,000 | 2,813,807 | 2/1/2018 | Quarterly | 9/30/2023 | |||||||
Hill City Capital Offshore Fund Ltd., Class A, Series 14 | 6.4% | 1,750,000 | 2,051,329 | 11/1/2021 | Quarterly | 9/30/2023 | (3) | ||||||
TCIM Offshore Fund Ltd., Class A-33, Series 2019-12 | 7.9% | 1,756,890 | 2,536,633 | 12/1/2019 | Monthly | 7/31/2023 | |||||||
Thames Absolute Return Offshore Fund, Ltd., Class B-2, Series 1 | 5.8% | 1,550,000 | 1,861,055 | 11/1/2017 | Quarterly | 9/30/2023 | |||||||
Wolf Hill Offshore Fund, Ltd., Class A-OS, Series 2020-08 | 5.2% | 1,300,000 | 1,685,933 | 7/1/2021 | Quarterly | 9/30/2023 | |||||||
Total Long/Short Generalist | 44.1% | 10,384,337 | 14,203,399 | ||||||||||
Long/Short Sector: | |||||||||||||
Energy | |||||||||||||
Encompass Capital Fund Offshore Ltd., Class A, Series 1 | 10.8% | 1,803,039 | 3,461,916 | 1/1/2020 | Quarterly | 9/30/2023 | |||||||
Healthcare, Biotechnology | |||||||||||||
Avoro Life Sciences Offshore Fund Ltd., Class A-1 | 12.0% | 1,069,545 | 3,875,042 | 5/1/2017 | Quarterly | 9/30/2023 | |||||||
Biomedical Offshore Value Fund, Ltd., Class I, Series 200199-1 | 10.0% | 2,100,000 | 3,218,803 | 1/1/2019 | Quarterly | 9/30/2023 | |||||||
Total Healthcare, Biotechnology | 22.0% | 3,169,545 | 7,093,845 | ||||||||||
Healthcare, Consumer | |||||||||||||
Armistice Capital Offshore Fund Ltd., Class A, Series 2019-04B | 0.0% | (5) | 17,040 | 1,890 | 4/1/2019 | N/A | (4) | ||||||
Armistice Capital Offshore Fund Ltd., Class A, Series 2015-09B | 0.0% | (5) | 4,503 | 984 | 9/1/2015 | N/A | (4) | ||||||
Armistice Capital Offshore Fund Ltd., Class A, Series 2013-08B | 0.0% | (5) | 3,108 | 745 | 1/2/2015 | N/A | (4) | ||||||
Total Healthcare, Consumer | 0.0% | (5) | 24,651 | 3,619 | |||||||||
Technology, Media and Telecommunications | |||||||||||||
Atreides Foundation Fund, Ltd., Founders Class, Series F-2 | 8.3% | 1,585,524 | 2,657,282 | 5/15/2019 | Quarterly | 9/30/2023 | (3) | ||||||
Total Long/Short Sector | 41.1% | 6,582,759 | 13,216,662 | ||||||||||
Total Investments In Portfolio Funds | 85.2% | $ 16,967,096 | $ 27,420,061 |
Cross Shore Discovery Fund | |||||||||||||
Schedule of Investments (Unaudited) | |||||||||||||
June 30, 2023 | |||||||||||||
Money Market Funds | % of Net Assets |
Cost | Fair Value | Shares | ||||||||
Federated Hermes Institutional Prime Obligations Fund, | ||||||||||||
Institutional Class, 5.19%(6) | 8.7% | $ 2,810,761 | $ 2,810,604 | 2,810,322 | ||||||||
Total Investments | 93.9% | $ 19,777,857 | $ 30,230,665 | |||||||||
Other Assets in Excess of Liabilities | 6.1% | $ 1,966,946 | ||||||||||
Net Assets | 100.0% | $ 32,197,611 | ||||||||||
* Non-income producing security. | ||||||||||||
(1) There were no unfunded capital commitments as of June 30, 2023. | ||||||||||||
(2) Certain redemptions may be subject to various restrictions and limitations such as redemption penalties on investments liquidated within a certain period subsequent to investment (e.g., a soft or hard lock-up), investor-level gates and/or Portfolio Fund-level gates. Redemption notice periods range from 30 to 120 days. | ||||||||||||
(3) Subject to 25% investor level quarterly gate. | ||||||||||||
(4) Redemptions are not permitted until the underlying special investments are sold/liquidated. | ||||||||||||
(5) Amount is less than 0.05%. | ||||||||||||
(6) Rate disclosed is the seven day effective yield as of June 30, 2023. |